About Us | Contact

Lyle R Gesner Investigator

Diagnostic Radiology Saint Barnabas Medical Center NPI1023055654
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$119,020.80
from 29 payments in the last 6 years

Total Cash or Cash Equivalent

$118,975.00
from 28 payments in the last 6 years

Total In-kind Items & Services

$45.80
from 1 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
10/07/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $2520.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 848675791
07/12/2021 Research Cash or cash equivalent Drug $350.00 Details
Payment from Novartis Pharmaceuticals Corporation
Paymment Research Study PHASE 2 STUDY OF DABRAFENIB AND TRAMETINIB IN PATIENTS WITH TUMORS WITH BRAF V600E OR V600K MUTATIONS (EXCLUDING MELANOMA AND THYROID CANCER)
Payment Record ID 800609455
09/10/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $7136.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 747776263
11/08/2018 Research Cash or cash equivalent Biological $1545.00 Details
Payment from EMD Serono, Inc.
Paymment Research Study EMR 200647-001
Payment Record ID 717748889
10/04/2018 Research Cash or cash equivalent Biological $600.00 Details
Payment from EMD Serono, Inc.
Paymment Research Study EMR 200647-001
Payment Record ID 717748887
03/27/2019 General (Non-Research) In-kind items and services Food and Beverage $45.80 Details
Payment from Medtronic USA, Inc.
Payment Record ID 667609471
04/04/2019 Research Cash or cash equivalent Drug $380.00 Details
Payment from Novartis Pharmaceuticals Corporation
Paymment Research Study A PHASE III MULTICENTER RANDOMIZED STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN PREVIOUSLY UNTREATED ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE STAGE IIIB OR IV NON SQUAMOUS NON SMALL CELL LUNG CANCER
Payment Record ID 640705163
02/07/2019 Research Cash or cash equivalent Drug $12250.00 Details
Payment from Novartis Pharmaceuticals Corporation
Paymment Research Study ROAR A PHASE II OPEN LABEL STUDY IN SUBJECTS WITH BRAF V600E MUTATED RARE CANCERS WITH SEVERAL HISTOLOGIES TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF THE COMBINATION THERAPY OF DABRAFENIB AND TRAMETINIB
Payment Record ID 640705159
11/08/2018 Research Cash or cash equivalent $1545.00 Details
Payment from EMD Serono, Inc.
Paymment Research Study EMR 200647-001
Clinical Trials Gov ID NCT02517398
Payment Record ID 612264089
05/23/2018 General (Non-Research) Cash or cash equivalent Consulting Fee $2643.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 604532033
01/04/2018 Research Cash or cash equivalent Drug $10670.00 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study ROAR A PHASE II OPEN LABEL STUDY IN SUBJECTS WITH BRAF V600E MUTATED RARE CANCERS WITH SEVERAL HISTOLOGIES TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF THE COMBINATION THERAPY OF DABRAFENIB AND TRAMETINIB
Payment Record ID 584630887
12/07/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $2159.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504812817
09/07/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $4380.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504547911
05/11/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $2475.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503951031
01/25/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $2460.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503584393
03/16/2017 Research Cash or cash equivalent Drug $6220.00 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study ROAR A PHASE II OPEN LABEL STUDY IN SUBJECTS WITH BRAF V600E MUTATED RARE CANCERS WITH SEVERAL HISTOLOGIES TO INVESTIGATE THE CLINICAL EFFICACY AND SAFETY OF THE COMBINATION THERAPY OF DABRAFENIB AND TRAMETINIB
Payment Record ID 489834151
03/09/2017 Research Cash or cash equivalent Drug $2315.00 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE ADVANCED NON SMALL CELL LUNG CANCER WHO HAVE BEEN TREATED PREVIOUSLY WITH CHEMOTHERAPY PLATINUM DOUBLET AND CRIZOTINIB
Payment Record ID 489834117
03/09/2017 Research Cash or cash equivalent Drug $2290.00 Details
Payment from NOVARTIS PHARMACEUTICALS CORPORATION
Paymment Research Study A PHASE III MULTICENTER RANDOMIZED STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN PREVIOUSLY UNTREATED ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE STAGE IIIB OR IV NON SQUAMOUS NON SMALL CELL LUNG CANCER
Payment Record ID 489834109
06/06/2016 Research Cash or cash equivalent Drug $18295.00 Details
Payment from Novartis Pharmaceuticals Corporation
Paymment Research Study A PHASE III MULTICENTER RANDOMIZED STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN PREVIOUSLY UNTREATED ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE STAGE IIIB OR IV NON SQUAMOUS NON SMALL CELL LUNG CANCER
Payment Record ID 407679368
05/16/2016 Research Cash or cash equivalent Drug $13310.00 Details
Payment from Novartis Pharmaceuticals Corporation
Paymment Research Study A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY OF ORAL LDK378 VERSUS STANDARD CHEMOTHERAPY IN ADULT PATIENTS WITH ALK REARRANGED ALK POSITIVE ADVANCED NON SMALL CELL LUNG CANCER WHO HAVE BEEN TREATED PREVIOUSLY WITH CHEMOTHERAPY PLATINUM DOUBLET AND CRIZOTINIB
Payment Record ID 407679366
06/09/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $4083.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406487180
11/17/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $663.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406485690
09/01/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3751.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406066050
08/04/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $1604.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405795150
06/02/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $7143.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405740756
05/25/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $1380.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405729262
01/07/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $780.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405704412
01/07/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3840.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405704406
03/31/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $2188.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405697614
;